A multi-center, randomized, double-blind, parallel-group study to investigate the pharmacokinetics, pharmacodynamics, safety and tolerability of multiple inhaled NVA237 doses at four dose levels in COPD patients.

Trial Profile

A multi-center, randomized, double-blind, parallel-group study to investigate the pharmacokinetics, pharmacodynamics, safety and tolerability of multiple inhaled NVA237 doses at four dose levels in COPD patients.

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Feb 2012

At a glance

  • Drugs Glycopyrrolate (Primary)
  • Indications Chronic obstructive pulmonary disease
  • Focus Pharmacokinetics
  • Sponsors Novartis
  • Most Recent Events

    • 01 Feb 2012 Results published in the International Journal of Clinical Pharmacology and Therapeutics.
    • 22 Sep 2010 Results presented at the 20th Annual Congress of the European Respiratory Society.
    • 07 Jan 2008 Status changed from in progress to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top